Berry B W, Jamali F
Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, Canada.
J Pharmacol Exp Ther. 1991 Aug;258(2):695-701.
Fenoprofen (FN), a member of the 2-arylpropionic acid (2-APA) class of nonsteroidal anti-inflammatory drugs is administered clinically as a racemate. In humans, FN has been shown to rapidly undergo substantial in vivo unidirectional chiral inversion with the inactive R-isomer converted to its active antipode. As with any p.o. administered drug, before reaching the systemic circulation. FN may undergo first-pass metabolism, the major organs involved being the gastrointestinal tract and/or the liver. The site(s) of inversion for the 2-APAs have been a subject of debate, with presystemic intestinal metabolism in humans and hepatic systemic metabolism in rats receiving the most attention. The inversion of R-FN was studied in the male Sprague-Dawley rat 1) in vivo after p.o. and i.v. administration of racemic-FN and R-FN, 2) after perfusion of R-FN into isolated liver (single-pass and recirculation) and 3) after a 2-hr incubation with everted intestinal tissue (duodenum, jejunum, ileum and colon) and noneverted stomach pouch. The enantiomers and their acyl-glucuronides were quantitated using a previously developed stereospecific assay. With the isolated liver, R-FN was shown to invert in both the single-pass and recirculation systems, with a first-pass extraction ratio of 0.3. A significant but variable inversion in all intestinal segments was observed. Substantial inversion by the duodenum was observed (serosal S:R ratio, 1.2) with maximal inversion by the jejunum (serosal S:R ratio, 2.2), whereas inversion of R-FN was absent in the stomach. Considerable glucuronidation was observed in all tissues studied including first-pass glucuronidation of both enantiomers after single-pass perfusion through the isolated liver and stereoselective glucuronidation in intestinal tissue segments. The results indicate that, in the male Sprague-Dawley rat, R-FN undergoes presystemic inversion by both the gastrointestinal tract and liver. These results, however, must be viewed with caution as they may not necessarily be extrapolated to other 2-APAs or species.
非诺洛芬(FN)是2-芳基丙酸(2-APA)类非甾体抗炎药的一种,临床上以消旋体形式给药。在人体中,FN已被证明在体内会迅速发生大量单向手性转化,无活性的R-异构体转化为其活性对映体。与任何口服给药的药物一样,在进入体循环之前,FN可能会经历首过代谢,主要涉及的器官是胃肠道和/或肝脏。2-APA的手性转化位点一直是一个有争议的话题,人体的肠前代谢和大鼠的肝脏全身代谢受到了最多的关注。在雄性Sprague-Dawley大鼠中研究了R-FN的转化情况:1)口服和静脉注射消旋FN和R-FN后的体内情况;2)将R-FN灌注到离体肝脏(单次通过和再循环)后;3)与外翻肠组织(十二指肠、空肠、回肠和结肠)和未外翻胃袋孵育2小时后。使用先前开发的立体特异性测定法对映体及其酰基葡糖醛酸进行定量。在离体肝脏中,R-FN在单次通过和再循环系统中均发生转化,首过提取率为0.3。在所有肠段均观察到显著但可变的转化。十二指肠发生了大量转化(浆膜侧S:R比值为1.2),空肠转化最大(浆膜侧S:R比值为2.2),而胃中未观察到R-FN的转化。在所有研究的组织中均观察到大量葡糖醛酸化,包括单次通过灌注离体肝脏后两种对映体的首过葡糖醛酸化以及肠组织段中的立体选择性葡糖醛酸化。结果表明,在雄性Sprague-Dawley大鼠中,R-FN在胃肠道和肝脏中均发生肠前转化。然而,这些结果必须谨慎看待,因为它们不一定能外推到其他2-APA或物种。